Par Pharma snags new COO from Glenmark; GSK says patients prefer Votrient; Sanofi wins expanded use for tDAP shot;

@FiercePharma: Industry predicts dire consequences from FDA's generic labeling proposal. News | Follow @FiercePharma

@TracyStaton: GSK ditches ovarian cancer plans for Votrient after failed study. More | Follow @TracyStaton

@EricPFierce: GSK attacks African market with combo of goodwill, R&D and plant projects. Article | Follow @EricPFierce

@CarlyHFierce: Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up- FiercePharmaMarketing. Story | Follow @CarlyHFierce

> Par Pharmaceutical, based in Woodcliff Lake, NJ, brought on Terrance Coughlin as chief operating officer; previously, he was president and CEO of Glenmark Generics' U.S. group. Release

> GlaxoSmithKline ($GSK) touted a new study showing that its kidney cancer drug Votrient was preferred by patients, compared with Pfizer's ($PFE) competing treatment, Sutent. Report

> Sanofi ($SNY) said its vaccines division won expanded FDA approval for its Adacel combination vaccine, in children 10 years of age. Release

> AstraZeneca ($AZN) is rolling out cloud-based human resources software to 66,000 staff around the globe. Report

> Germany-based Merck Serono is mounting an effort to increase biomarker testing in patients with metastatic colorectal cancer. Report

> Johnson & Johnson ($JNJ) has signed on as the official healthcare partner of the USO. Report

Medical Device News

@FierceMedDev: Four months later 23andMe's clash with the FDA over regulation of OTC genetic tests remains unresolved. Story | Follow @FierceMedDev

@MarkHFierce: Check out the latest FierceDiagnostics, with news involving Pfizer, colon cancer tests and HIV Dx funding. Report | Follow @MarkHFierce

@MichaelGFierce: In drug delivery, it's the little things that count. Looking back on the year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Researchers at Cornell delve into "cereal box psychology" with new study on supermarkets and spokes-characters. Article | Follow @EmilyWFierce

> Thoratec smacked with FDA Class I recall concerning heart pump backup controllers. More

> Boston Scientific touts promising trial data for its transcatheter valve. Story

> Cepheid's 60-minute HPV test is now available in Europe. Item

Biotech News

@FierceBiotech: Stallergenes beats Merck to market as the FDA OKs its allergy pill. More | Follow @FierceBiotech

@JohnCFierce: Analysts, experts are dazzled by the blockbuster potential of Novartis' LCZ696. News | Follow @JohnCFierce

@DamianFierce: MannKind jumps ~125% after positive panel vote, reaching a four-year high. Story | Follow @DamianFierce

@EmilyMFierce: Most popular at FierceBiotechResearch.com: Committee finds 'scientific misconduct' in blockbuster stem cell papers. Article | Follow @EmilyMFierce

> GlaxoSmithKline shutters lung cancer vaccine study on latest MAGE-A3 setback. News

> Baxter snaps up its hemophilia partner on the verge of a biotech breakup. Story

Drug Delivery News

> Enzyme micropumps deliver insulin in response to glucose levels. Story

> Hydrogel delivers inhibitors directly to reduce damage after a heart attack. Article

> Harvard researchers create method to measure nano exposure for safety, delivery. News

> Water excited by infrared light melts nanoparticles to release drugs. Article

> DNA nanorobot delivers drugs through flap that opens and closes. Story

> Wearable data-storing 'electronic skin' could deliver drugs for epilepsy, Parkinson's. Brief

Diagnostics News

> Pfizer leads $21M Series B for a Michigan molecular Dx startup. News

> Exact Sciences' and Epigenomics' colon cancer tests clear FDA panel with mixed results. News

> New septic shock biomarker Dx could produce better care and smoother drug trials. Article

> U.K. team scores with blood test that might spot children likely to become obese. Story

> Zyomyx snags $7.5M from WHO's UNITAID to fund HIV/AIDS test in emerging markets. News

> Finding: 2 biomarkers for head and neck cancer can help predict radiation therapy resistance. Brief

Pharma Marketing News

> Sanofi aims for outcomes with brand-new Chief Patient Officer. Story

> Eli Lilly's sales force finds CRM harmony in the cloud. Article

> Biogen's Alprolix nod is just the first tremor in a hemophilia market shake-up. Story

> Can statin-maker Kowa help Amarin jump-start Vascepa sales? Article

> Auxilium aims Stendra's sexy March Madness ads at stiff ED competition. Story

> ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries. Brief

And Finally... Two big studies found links between low vitamin D levels and deadly disease, but couldn't determine whether low levels cause disease or indicate disease-causing behaviors such as an unhealthy diet. Report

Suggested Articles

Look out, diabetes market: Novo Nordisk won its FDA nod for highly anticipated Rybelsus to control blood sugar in patients with Type 2 diabetes.

Insys is in fire sale mode as part of its bankruptcy plan, and now it’s been given the go-ahead to sell the opioid that helped get it there.

GSK CEO Emma Walmsley could soon have a new title: Microsoft board member. The software giant has nominated her to its board of directors.